Obinutuzumab for Lupus Nephritis Boosts Complete Remissions

(MedPage Today) — Adding a monoclonal antibody approved for blood cancer indications to standard therapy for adults with active lupus nephritis outperformed standard therapy alone in a phase III trial.
In the REGENCY study, 46.4% of patients…

Source link : https://www.medpagetoday.com/rheumatology/lupus/114139

Author :

Publish date : 2025-02-07 22:37:22

Copyright for syndicated content belongs to the linked Source.